Safety and efficacy of human IgE pentapeptide.
The safety, dosage and efficacy of human IgE pentapeptide (HEPP) was evaluated in 12 patients with IgE-mediated atopic disease. Statistically significant differences were observed in allergy symptom scores, allergy medication usage and skin test results between the HEPP treatment and placebo control groups. HEPP appears to be a safe, new therapeutic modality for the treatment of allergic disease.
D000328:Adult; D002986:Clinical Trials as Topic; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D006969:Hypersensitivity, Immediate / Q000175:diagnosis; D007073:Immunoglobulin E / Q000008:administration & dosage* / Q000502:physiology; D007165:Immunosuppression Therapy; D007167:Immunotherapy / Q000592:standards*; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000008:administration & dosage* / Q000502:physiology; D010919:Placebos; D012044:Regression Analysis; D012882:Skin Tests
D010446:Peptide Fragments; D010919:Placebos; D007073:Immunoglobulin E; C040297:pentigide